Introduction

How TNF inhibitors ushered new hope and promise for patients with inflammatory arthritis

It is a quarter of a century since the first biologics, the tumour necrosis factor inhibitors (TNFi) infliximab and etanercept, were approved for the treatment of rheumatoid arthritis (RA). The initial positive experience with these agents provided proof of concept that targeting key molecular and cellular components of chronic inflammation was an effective and safe treatment strategy in RA.

Genetics of rheumatoid arthritis in sub-Saharan Africans

Rheumatoid arthritis (RA) is a chronic arthritis characterised by inflammation of synovial lined joints affecting approximately 0.5-1% of the adult population worldwide. Although not entirely understood, an interaction of genetic and environmental factors are thought to play a role in the aetiopathogenesis of RA. Twin studies supports the notion of a genetic predisposition with a higher concordance in monozygotic twins (15%) versus dizygotic twins (3.5%).

Artificial intelligence in musculoskeletal disease detection

Machine Learning techniques, a subcategory of AI, will enable a higher level of capability in evidencebased decision-making, driving the growth in applications of AI and fueling the boom of AI.

Basics of “-omics” for the rheumatologist: Unveiling the molecular complexity

The integration of omics technologies in CTD research has revolutionised our understanding of the autoimmune diseases (ADs), enabling the identification of biomarkers and molecular mechanisms that were previously unknown.

Case report: Antiphospholipid syndrome with concomitant systemic lupus erythematosus in a child

Pediatric systemic lupus erythematosus (pSLE) is an autoimmune disorder, characterised by more severe multi-system involvement than in adults, occurring in children before the age of 18, and accounting for 15-20 % of all SLE cases. There is presently lack of data on incidence and prevalence of pSLE in Africa with a small study done only in South Africa (Lewandowski et al).

Accreditation

Health Professions Council of South Africa

MDB015/443/02/2024

2 Clinical

Certification

Attempts allowed: 2

70% pass rate





Enquire Now

News Rheum - Vol 4 No 2 - February 2024